IP Library Granted Patent US 9,956,289
Granted Patent B2
US 9,956,289 · App. 14/943,649 · Granted May 1, 2018

Emulsion compositions containing quaternary ammonium compounds

Inventors: Laura Rabinovich-Guilatt (Kadima, IL); Gregory Lambert (Chatenay Malabry, FR); Frederic Lallemand (Fresnes, FR); Betty Philips (Antony, FR)
Assignee: SANTEN SAS
A61K47/186A61K9/0014A61K9/0048A61K9/107A61K31/14A61K31/765A61K38/13A61L12/143C07C211/63
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,956,289
App. No.
14/943,649
Granted
May 1, 2018
Kind
B2
Abstract

Compositions containing quaternary compounds in which the nitrogen atom is substituted by at least one alkyl group having at least 12 carbon atoms, and the composition includes at least 20% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 14 carbon atoms and more than 5%, preferably more than 7% in weight by weight of the total composition, of ammonium halides in which the nitrogen atom is substituted by at least one alkyl group having at least 16 carbon atoms. Also, ophthalmic oil-in-water emulsions containing such compositions, the ophthalmic emulsions being useful for eye care or for the treatment of eye conditions.

Claims (22)

1. An oil-in-water emulsion comprising:

an oil phase comprising mineral oil, castor oil or medium chain triglycerides;

0.0005% to 0.1% w/w of ammonium halide, cetalkonium chloride being the sole ammonium halide of the emulsion; and

0.1% to 1% w/w of surfactant selected from the group consisting of tyloxapol, poloxamer 188, tocopherol polyethylene glycol succinate and mixtures thereof.

2. The oil-in-water emulsion according to claim 1 , wherein the mineral oil phase is a mixture of heavy and light mineral oil.

3. The oil-in-water emulsion according to claim 1 , further comprising buffering agents and/or at least one tonicity agent.

4. The oil-in-water emulsion according to claim 3 , wherein the tonicity agent is mannitol.

5. The oil-in-water emulsion according to claim 3 , wherein the tonicity agent is glycerol.

6. The oil-in-water emulsion according to claim 1 , said emulsion having a positive zeta potential.

7. The oil-in-water emulsion according to claim 1 , said emulsion having a droplet size of 100 to 500 nm.

8. The oil-in-water emulsion according to claim 1 , said emulsion comprising light and heavy mineral oil, tyloxapol, poloxamer 188, mannitol and cetalkonium chloride.

9. The oil-in-water emulsion according to claim 1 , said emulsion comprising light and heavy mineral oil, tyloxapol, poloxamer 188, glycerol and cetalkonium chloride.

10. The oil-in-water emulsion according to claim 1 , said emulsion being hypotonic, relative to normal tears.

11. The oil-in-water emulsion according to claim 1 , wherein said emulsion is suitable for ophthalmic use.

12. The oil-in-water emulsion according to claim 1 , said emulsion being less toxic than a solution comprising the same amount of cetalkonium chloride, in weight by weight of the solution.

13. The oil-in-water emulsion according to claim 1 , further comprising an active principle.

14. The oil-in-water emulsion according to claim 13 , wherein the active principle is cyclosporine.

15. A medicament comprising the oil-in-water emulsion according to claim 1 .

16. The medicament according to claim 15 , wherein said emulsion is suitable for ophthalmic use.

17. A method for preparing an ophthalmic composition for dry eye treatment, comprising preparing the emulsion according to claim 1 .

18. A kit for dry eye treatment comprising a first emulsion according to claim 1 and a second emulsion containing cyclosporine.

19. The oil-in-water emulsion according to claim 1 , wherein said emulsion comprises medium chain triglycerides, tyloxapol, poloxamer 188, glycerol and cetalkonium chloride.

Assignments (3)
CHANGE OF ADDRESS Recorded Feb 20, 2025
From: SANTEN
To: SANTEN
Reel/Frame 070276/0582 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2015
From: RABINOVICH-GUILATT, LAURA; LAMBERT, GREGORY; LALLEMAND, FREDERIC; PHILIPS, BETTY
To: NOVAGALI PHARMA SA
Reel/Frame 037062/0972 →
CHANGE OF NAME Recorded Nov 17, 2015
From: NOVAGALI PHARMA SA
To: SANTEN SAS
Reel/Frame 037126/0822 →
Continuity (3)
Continuation 13957621 · Aug 2, 2013
Continuation In Part 13096512 · Apr 28, 2011
Related Publication 20160082107A1 · Mar 24, 2016